Meeting
2023 ASCO Annual Meeting
Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting.
Authors
Sudipto Mukherjee
Cleveland Clinic, Cleveland, OH
Sudipto Mukherjee , Cherrishe Brown-Bickerstaff , Angelica Falkenstein , Adeola Y. Makinde , Emily Bland , JaLyna Laney , Marné Garretson , Ali McBride
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7057)
DOI
10.1200/JCO.2023.41.16_suppl.7057
Abstract #
7057
Poster Bd #
187
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Clinical and economic effects of technology updates to the electronic health record for the management of erythopoetic stimulating agents and MDS-associated anemia.
First Author: Steven Gilmore
Poster
2023 ASCO Annual Meeting
Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).
First Author: Adeola Y. Makinde
Poster
2022 ASCO Annual Meeting
Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.
First Author: Pierre Fenaux
Poster
2022 ASCO Annual Meeting
Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.
First Author: Abhishek Avinash Mangaonkar